Muscular Dystrophy Pipeline Review, H1 2018 - Covering Companies Involved, Drug Profiles, Dormant Projects and Discontinued Products - ResearchAndMarkets.com
Jun. 11, 2018
DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The "Muscular Dystrophy - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 2, 1, 29 and 14 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 6 molecules, respectively.
Companies MentionedAcceleron Pharma Inc Achelios Therapeutics Inc AMO Pharma Ltd Benitec Biopharma Ltd Bio Blast Pharma Ltd Biophytis SA Corcept Therapeutics Inc Evotec AG Fulcrum Therapeutics Inc Genethon SA Gilead Sciences Inc Marina Biotech Inc Pfizer Inc Prothelia Inc Recursion Pharmaceuticals Inc Resverlogix Corp SanBio Inc Santhera Pharmaceuticals Holding AG Sarepta Therapeutics Inc Strykagen Corp Ultragenyx Pharmaceutical Inc
Key Topics CoveredIntroduction Muscular Dystrophy - Overview Muscular Dystrophy - Therapeutics Development Muscular Dystrophy - Therapeutics Assessment Muscular Dystrophy - Companies Involved in Therapeutics Development Muscular Dystrophy - Drug Profiles Muscular Dystrophy - Dormant Projects Muscular Dystrophy - Discontinued Products Muscular Dystrophy - Product Development Milestones Appendix
For more information about this report visit https://www.researchandmarkets.com/research/644jkk/muscular?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005923/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs ,Musculoskeletal Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/11/2018 01:06 PM/DISC: 06/11/2018 01:06 PM